STAR-PARK: Modulation of Cognitive Control Via Transcranial Continuous Electrical Stimulation of Additional Motor Areas in Parkinson's Patients

Sponsor
Assistance Publique Hopitaux De Marseille (Other)
Overall Status
Recruiting
CT.gov ID
NCT04897633
Collaborator
(none)
72
1
3
19
3.8

Study Details

Study Description

Brief Summary

In Parkinson's disease (PD), recent work has shown that dopaminergic treatments alter one of the two aspects of impulsivity: they do not alter the propensity to produce "automatic" responses, but deteriorate the ability to inhibit and correct (that is, control) them. In healthy subjects, the investigator's team has also demonstrated that transcranial direct current "cathodal" electrical stimulation (tDCS) of Supplementary Motor Areas decreases the frequency of behavioral errors by improving the ability to "correct" responses.

The main objective of this project is to determine whether cathodal tDCS of Supplementary Motor Areas in PD patients under dopaminergic treatment improves the control and correction of errors about to be made and compensates for the deficits induced by the treatment.

All participants will perform a reaction time task of choice (Simon's task), with and without ("sham" session) tDCS. The experimental design of this single-center, single-blind, randomized study will be that of 3 parallel groups (treated Parkinson's disease, untreated Parkinson's disease patient, and matched control subjects) with cross-over application of tDCS. All participants will be blind to the operating mode of the tDCS (either functional or in "sham" mode corresponding to a control condition). The order of the sessions (with and without tDCS) will be randomized within each of the 3 groups of subjects. The analysis of errors about to be made but inhibited in time (known as "early errors") will be carried out through electromyographic (surface) recording of muscle activities involved in motor responses.

tDCS is expected to improve the ability of treated patients to correct their errors about to be made. This study will thus provide a better understanding of the mechanisms of action control and possibly propose a new therapeutic approach for treatment-induced impulsivity disorders in Parkinson's disease.

Condition or Disease Intervention/Treatment Phase
  • Device: transcranial electric stimulation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
72 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Modulation of Cognitive Control Via Transcranial Continuous Electrical Stimulation of Additional Motor Areas in Parkinson's Patients
Actual Study Start Date :
Jun 2, 2021
Anticipated Primary Completion Date :
May 28, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients ON

Patients will performed Simon's task with tDCS active or sham when treatment is OFF (for standard care procedure)

Device: transcranial electric stimulation
Simon's task assessment when under tDCS
Other Names:
  • DC STIMULATOR PLUS
  • Experimental: Patients OFF

    Patients will performed Simon's task with tDCS active or sham when treatment is ON (for standard care procedure)

    Device: transcranial electric stimulation
    Simon's task assessment when under tDCS
    Other Names:
  • DC STIMULATOR PLUS
  • Experimental: Healthy volunteers

    Healthy volunteers will performed Simon's task with tDCS active or sham

    Device: transcranial electric stimulation
    Simon's task assessment when under tDCS
    Other Names:
  • DC STIMULATOR PLUS
  • Outcome Measures

    Primary Outcome Measures

    1. Rapid error rate. [Day 2]

      Responses recorded on the opposite side to that expected

    2. Rapid error rate. [Day 3]

      Responses recorded on the opposite side to that expected

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria for Parkinsonien patients:
    • Age> 18 years old

    • Idiopathic Parkinson's disease meeting the diagnostic criteria as defined by Ward and Gibb (1990)

    • Patients usually taking dopaminergic treatment.

    • No cognitive deterioration with: a Montreal Cognitive Assessment (MoCA) score ≥ 26

    • Patient with Parkinson's disease in the advanced motor complications stage for which surgical treatment is being considered

    Inclusion Criteria for healthy subjects

    • Age> = 18 years old

    • Patient free from Idiopathic Parkinson's Disease

    • No cognitive deterioration: MMSE (MiniMentalSate Evaluation)> 26

    Exclusion Criteria for both parkinsonien patients an healthy volunteers:
    • Uncorrected altered visual acuity

    • Dyschromatopsia (especially color blindness)

    • Psychotropic treatment introduced or modified recently (<1 month)

    • Wearing a pacemaker (Pace Maker or Implantable Defibrillator)

    • Pregnancy (verified by a urine pregnancy test for women of childbearing age)

    • Other central nervous system disease (other parkinsonian syndrome, epilesia, stroke, etc.) or peripheral

    • Intracranial metal implants on the cephalic stage and cochlear implant

    • Untreated progressive mood or psycho-behavioral disorder

    • Severe and poorly controlled eczema

    Exclusion criteria for Parkinson's patients only:
    • Significant and disabling abnormal movement, not allowing good acquisition of the EMG signal (tremors or dyskinesias)

    • Wearer of a Deep Brain Stimulation device (CI at tDCS).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Service Neurologie et pathologies du mouvement Marseille France 13005

    Sponsors and Collaborators

    • Assistance Publique Hopitaux De Marseille

    Investigators

    • Study Director: Jean Olivier ARNAUD, APHM

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Assistance Publique Hopitaux De Marseille
    ClinicalTrials.gov Identifier:
    NCT04897633
    Other Study ID Numbers:
    • 2019-46
    • ID-RCB
    First Posted:
    May 21, 2021
    Last Update Posted:
    Jul 20, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Assistance Publique Hopitaux De Marseille
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 20, 2021